Dako PD-L1 检测试剂盒（免疫组织化学法）判读培训教程
PD-L1 是经证实，可以用于预测食管鳞状细胞癌 (ESCC) 患者是否能从 KEYTRUDA®（帕博利珠单抗）治疗获益的生物标记物（PD-L1 检测试剂盒（免疫组织化学法）[说明书]，2021）。 本教程旨在回顾并介绍如何正确使用 PD-L1 检测试剂盒（免疫组织化学法）和联合阳性评分 (CPS) 对 PD-L1 表达进行判读与评分。
Dako PD-L1 检测试剂盒（免疫组织化学法）判读培训教程通过问答互动与提供实际病例供练习的方式，帮助您准确地：
- 了解 PD-L1 病理学的核心原则
- 了解PD-L1 染色标本的评估步骤
- 识别影响 PD-L1 判读的常见影响因素
- 对各种患者标本染色图像进行 PD-L1 表达评分
了解 PD-L1 检测试剂盒
（免疫组织化学法） 预期用途
（免疫组织化学法） 预期用途
对于美国以外的国家/地区，请参阅当地的 KEYTRUDA 产品标签，了解批准的适应症及临界值以指导治疗。
开始体验
立即注册
已经注册？
立即登录
参考文献
- Keytruda [prescribing information].Kenilworth, NJ: Merck & Co.; 2021.
- PD-L1 检测试剂盒（免疫组织化学法）[说明书]，Carpinteria, CA: Dako，安捷伦病理学解决方案；2021。
- Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.;, Kohrt, H.E.; Horn, L.; Lawrence, D.P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P.S.; Mellman, I.; Chen, D.S.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature.2014, 515 (7528), 563-567.
- Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; West, AN.; Carmona, M.; Kivork, C.; Seja, E.; Cherry, G.; Gutierrez, A.J.; Grogan, T.R.; Mateus, C.; Tomasic, G.; Glaspy, J.A.; Emerson, R.O.; Robins, H.; Pierce, R.H.; Elashoff, D.A.; Robert, C.; Ribas, A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature.2014, 515 (7528), 568-571.
- Hanahan, D. Weinberg, R.A. Hallmarks of cancer: the next generation.Cell.2011, 144 (5), 646-674.
- Sharpe A.H. Freeman G.J. The B7-CD28 superfamily.Nat Rev Immunol.2002, 2 (2), 116-126.
- Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands intolerance and immunity. Annu Rev Immunol. 2008, 26, 677-704.
- Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; Horton, H.F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M.R.; Carreno, B.M.; Collins, M.; Wood, C.R.; Honjo, T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med.2000, 192 (7), 1027-1034.
- Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V.A.; Celis, E.; Chen, L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med.2002, 8 (8), 793-800.
- Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med.2012, 366 (26), 2455-2465.
- Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med.2012, 366 (26), 2443-2454.
- Roach, C.; Zhang, N.; Corigliano, E.; Jansson, M.; Toland, G.; Ponto, G.; Dolled-Filhart, M.; Emancipator, K.; Stanforth, D.; Kulangara, K. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016, 24, 392-397.
- Kojima, T.; Muro, K.; Francois, E.; Hsu, C.H.; Moriwaki, T.; Kim, S.B.; Lee, S.H.; Bennouna, J.; Kato, K.; Shen, L.; Qin, S.; Ferreira, P.; Doi, T.; Adenis, A.; Enzinger, P.; Shah, M.; Wang, R.; Bhagia, P.; Kang, S.P.; Metges, J.P. Pembrolizumab vs chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. J Clin Oncol. 2019, 37 (Supp 4), abstr 2.